Angiotensin 1-7 is an endogenous 7-amino-acid peptide (sequence: Asp-Arg-Val-Tyr-Ile-His-Pro, MW ~899.0 g/mol) formed primarily by ACE2-mediated cleavage of angiotensin II. It acts as a counter-regulatory arm of the renin-angiotensin system, opposing the vasoconstrictive and pro-inflammatory actions of angiotensin II. It remains in preclinical and early clinical investigation with no approved therapeutic indications.
Category: Cardiovascular / Vasoactive. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical and early-phase research. No approved therapeutic indication.
Angiotensin 1-7 signals primarily through the Mas receptor (MasR), a G-protein-coupled receptor. Activation of MasR stimulates nitric oxide (NO) and prostaglandin release, producing vasodilation and reducing vascular resistance. It activates PI3K/Akt/eNOS signaling to promote endothelial function,…
Safety considerations: No human safety data from controlled clinical trials; Hypotension is the expected pharmacological effect and primary risk; Extremely short plasma half-life necessitates continuous infusion or formulation modification for any therapeutic application.
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | Asp-Arg-Val-Tyr-Ile-His-Pro (DRVYIHP) |
|---|---|
| Molecular weight | ~899.0 g/mol |
| Half-life | <30 seconds (plasma) |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not approved. Research compound only. No FDA-approved products. |
Related peptides: Angiotensin II, Bradykinin, Endothelin-1.
Angiotensin 1-7 is produced by enzymatic cleavage of angiotensin II by ACE2. It acts as a physiological counterbalance to angiotensin II: while angiotensin II causes vasoconstriction, inflammation, and fibrosis via AT1 receptors, angiotensin 1-7 promotes vasodilation, anti-inflammation, and anti-fibrosis via the Mas receptor.
ACE2, which generates angiotensin 1-7, is the cell surface receptor used by SARS-CoV-2 for entry. It was hypothesized that viral binding to ACE2 reduces its enzymatic activity, depleting protective angiotensin 1-7 and tipping the RAAS balance toward pro-inflammatory angiotensin II effects. This contributed to interest in exogenous angiotensin 1-7 as a potential therapy, though clinical evidence…
No. Angiotensin 1-7 has no approved therapeutic use in any country. Its extremely short half-life and lack of human clinical trial data are major barriers to development. It is available only as a research-grade peptide.
Coverage on this site: Aclerastide: Effective Therapy for Diabetic Foot Ulcers.